Menu
Menu
864070-44-0
Anti-Diabetic
C23H27ClO7
450.9 g/mol
Amorphous
Pipeline
Ready
Ready
Empagliflozin is an anti-diabetic drug, falling under the class of blood glucose lowering drugs. It is used to lower blood sugar levels and reduce the risk of heart attack, stroke, or death in adults with type 2 diabetes mellitus. It reduces the risk of cardiovascular disease and death in adults with type 2 diabetes mellitus, specifically those with inadequate glycemic control. Empagliflozin is also prescribed to reduce the risk of hospitalization due to heart failure or cardiovascular death in non-hospitalized patients, regardless of diabetes status and the standard heart failure therapies they were already taking. The drug can be used as monotherapy or in combination with other glucose lowering medicines. Empagliflozin is administered through oral route by way of coated and film-coated tablets.
Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used for the improvement of glycaemic control in type 2 diabetes. SGLT2 is the main transporter that mediates reabsorption of glucose in the kidneys, from the glomerular filtrate back into the circulation. Empagliflozin improves glycaemic control by competitively inhibiting SGLT2, thereby reducing renal glucose reabsorption.
Ornet Pharmaceuticals, based out of Gujarat, India, is a leading manufacturer and global supplier of Empagliflozin API. Driven by technically sound, research-oriented leaders, each with over 2 decades of hands-on experience, Ornet develops and manufactures a wide array of complex APIs catering to multiple categories in its product portfolio, such as anti-diabetics, blood related, hormones, etc. Ornet’s Empagliflozin API is the result of the “Quality over Quantity” approach taken by the organization for all R&D and manufacturing practices. This approach, along with the strategically located manufacturing facility in Gujarat, allows for Ornet to be a primary source, both domestically and globally, for all API needs.
The above-mentioned product is presented solely for informational purposes and does not constitute an offer in any sense. Products with Pipeline status may be under patent protection and are not offered until expiration of the corresponding IP right.
